ACELRX PHARMACEUTICALS INC (ACRX)
US00444T2096 - Common Stock
| MRQ (2023-9-30) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 13.40M | 15.30M | 7.70M | 27.30M | 14.70M | |||
| Marketable Securities | 0.00 | 500.00K | 39.00M | 15.60M | 51.50M | |||
| Receivables | N/A | 300.00K | 200.00K | 600.00K | 500.00K | |||
| Inventories | N/A | 1.20M | 1.10M | 1.60M | 3.30M | |||
| Other Current Assets | 1.00M | 7.30M | 2.60M | 1.70M | 1.70M | |||
| Total Current Assets | 14.40M | 24.60M | 50.50M | 46.80M | 71.70M | |||
| Non-Current Assets | ||||||||
| PPE Net | N/A | 13.90M | 20.20M | 18.80M | 18.50M | |||
| Intangibles | 8.80M | 8.80M | 0.00 | N/A | N/A | |||
| Other Non-Current Assets | 0.00 | 200.00K | 7.20M | 700.00K | 900.00K | |||
| Total Non-Current Assets | 8.90M | 22.90M | 27.40M | 19.50M | 19.70M | |||
| TOTAL ASSETS | 23.30M | 47.50M | 77.90M | 66.30M | 91.40M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | 0.00 | 5.80M | 8.80M | 8.80M | 5.00M | |||
| Accrued Expenses | 1.80M | 5.90M | 7.50M | 6.00M | 6.50M | |||
| Accounts Payable | 1.00M | 2.00M | 2.10M | 2.70M | 1.70M | |||
| Other Current Liabilities | 800.00K | 100.00K | 100.00K | 0.00 | 400.00K | |||
| Total Current Liabilities | 3.60M | 13.80M | 18.50M | 17.60M | 13.60M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 5.00M | 13.10M | 20.50M | |||
| Other Non-Current Liabilities | 1.40M | 11.90M | 90.30M | 91.30M | 98.60M | |||
| Total Non-Current Liabilities | 1.40M | 11.90M | 95.30M | 104.40M | 119.20M | |||
| TOTAL LIABILITIES | 5.00M | 25.70M | 113.80M | 122.00M | 132.80M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -439.70M | -425.80M | -473.60M | -438.50M | -398.10M | |||
| Additional Paid In Capital | 458.00M | 447.60M | 437.70M | 382.60M | 356.60M | |||
| Common Shares | 0.00 | 0.00 | 0.00 | 100.00K | 100.00K | |||
| Other Shareholders' Equity | N/A | N/A | N/A | N/A | N/A | |||
| Shares Outstanding | 17.00M | 8.20M | 6.80M | 4.90M | 4.00M | |||
| Tangible Book Value per Share | 0.56 | 1.59 | -5.28 | -11.39 | -10.35 | |||
| Total Shareholders' Equity | 18.30M | 21.80M | -35.90M | -55.80M | -41.40M | |||
| TOTAL LIABILITIES AND EQUITY | 23.30M | 47.50M | 77.90M | 66.30M | 91.40M | |||
| Statistics | ||||||||
| Debt/Equity | N/A | N/A | -0.14 | -0.23 | -0.50 | |||
| Current Ratio | 4.00 | 1.78 | 2.73 | 2.66 | 5.27 | |||
| Return On Assets (ROA) | -113.65% | 89.12% | -45.06% | -60.90% | -58.25% | |||
| Return On Equity (ROE) | -144.70% | 194.17% | N/A | N/A | N/A | |||
All data in USD